Advertisement

Topics

SillaJen and NCI partner to develop new colorectal cancer treatment

19:00 EDT 17 Aug 2017 | Pharmaceutical Technology

Korean-based SillaJen has entered a cooperative research and development agreement (CRADA) with the National Cancer Institute (NCI), part of the National Institutes of Health (NIH), US, to develop a new combination therapy for colorectal cancer (CRC)…

Original Article: SillaJen and NCI partner to develop new colorectal cancer treatment

NEXT ARTICLE

More From BioPortfolio on "SillaJen and NCI partner to develop new colorectal cancer treatment"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

Collaborations in biotechnology
Commercial and academic collaborations are used throughout the biotechnology and pharmaceutical sector to enhance research and product development. Collaborations can take the form of research and evaluation agreements, licensing, partnerships etc. ...

Cancer
  Bladder Cancer Brain Cancer Breast Cancer Cancer Cervical Cancer Colorectal Head & Neck Cancers Hodgkin Lymphoma Leukemia Lung Cancer Melanoma Myeloma Ovarian Cancer Pancreatic Cancer ...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...